Impact of dosage timing on the bioavailability of oral anticancer medications: Is pre-prandial dosing equivalent to post-prandial dosing. (March 2019)

• Record Type: Journal Article
• Authors: Yu, Guo; Wu, Dan-Na; Yu, Yichao; Li, Guo-Fu; Zhou, Hong-Hao
• Is Part Of: Journal of oncology pharmacy practice. Volume 25:Number 2(2019)
• Page Start: 404
• Page End: 408
• Publication Date: 2019-03
• Subjects: Food timing -- oral oncology drugs -- bioavailability -- efficacy; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/1078155217752535
• Languages: English
• ISSNs: 1078-1552

Abstract

Many oral anticancer agents are recommended to be given either at least 1 h before or 2 h after a meal, according to the prescribing information. However, the effect of dosage timing of an oral anticancer agent with reference to food intake on anticancer treatment remains unclear. As shown by the literature survey and labeling analysis for oral anticancer drugs approved by the US Food and Drug Administration from 2010 to 2016, labeling information regarding dosage timing for several anticancer drugs appeared not be optimum, leading to suboptimal bioavailability and plasma drug concentrations. This supports a call to regularly recalibrate the labeling information for dosage timing of oral anticancer medications to minimize the risks of compromised efficacy or unintended toxicities.